Byakika-Kibwika, Pauline
Sekaggya-Wiltshire, Christine
Semakula, Jerome Roy
Nakibuuka, Jane
Musaazi, Joseph
Kayima, James
Sendagire, Cornelius
Meya, David
Kirenga, Bruce
Nanzigu, Sarah
Kwizera, Arthur
Nakwagala, Fred
Kisuule, Ivan
Wayengera, Misaki
Mwebesa, Henry G.
Kamya, Moses R.
Bazeyo, William
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial
https://doi.org/10.1186/s12879-021-06897-9
Article History
Received: 8 May 2021
Accepted: 22 November 2021
First Online: 6 December 2021
Declarations
:
: Ethics approval was obtained from the Makerere University School of Medicine Research and Ethics Committee (#REC REF 2020-137), the Uganda National Council for Science and Technology (RESCLEAR/05) and the National Drug Authority (CTA 0143). Written informed consent was obtained from all study participants and the trial was conducted according to Good Clinical Practice Guidelines in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare no conflict of interest for this work.